← Leaderboards
Charles Keller
University Of Utah
$6,992,058
Attributed
$7,776,185
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $668.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,776,185 · 7
By mechanism
R01$6,668,752 · 4
K08$697,005 · 1
R43$270,428 · 1
R03$140,000 · 1
Top collaborators
- Denis C Guttridge5 shared
Most similar at University Of Utah
Same institution · by research overlap
- Kuberan Balagurunathan$7,403,674
- Mario R Capecchi$17,194,081
- Richard David Bland$7,249,780
- Weiquan (wendy) Zhu$2,932,948
- Steven B Bleyl$673,650
Others in their field
Top investigators on “Rhabdomyosarcoma”
- James R Anderson · National Childhood Cancer Foundation$32,618,979
- Meenakshi Devidas · University Of Florida$21,702,062
- Gregory H Reaman · National Childhood Cancer Foundation$18,332,016
- Timothy J. Triche · University Of Southern California$15,978,109
- David Michael Langenau · Massachusetts General Hospital$15,287,445
- Peter J Houghton · University Of Texas Hlth Science Center$11,138,421
Research focus
RhabdomyosarcomaMediatingSignal TransductionTumorAlveolar RhabdomyosarcomaMalignant NeoplasmsChildhoodMolecularCellsResponseMalignant Muscle NeoplasmGeneticInsightTherapeutic TargetChildBaseIn VivoTreatment FailureNeoplastic CellProteinsComplexLymphaticClinical TrialsMutation
Grant awards (32)
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$303,780
R01 · FY2025 · CA · contact PI
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$288,592
R01 · FY2024 · CA · contact PI
Reimagining Pharmaceutical Drug Development in Oncology with a Biomimetic Platform$270,428
R43 · FY2024 · OD · contact PI
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$297,704
R01 · FY2023 · CA · contact PI
Pilot Project Investigating the PAX3-FOXO1 Protein in the Rare Disease Rhabdomyosarcoma$140,000
R03 · FY2023 · TR · contact PI
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$297,704
R01 · FY2022 · CA · contact PI
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$303,780
R01 · FY2021 · CA · contact PI
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$328,393
R01 · FY2019 · CA · contact PI
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$338,550
R01 · FY2018 · CA · contact PI
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$337,941
R01 · FY2017 · CA · contact PI
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$322,447
R01 · FY2016 · CA · contact PI
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$354,563
R01 · FY2015 · CA · contact PI
Elucidating the role of NF-kB signaling in rhabdomyocarcoma$314,344
R01 · FY2015 · CA
Elucidating the role of NF-kB signaling in rhabdomyocarcoma$304,913
R01 · FY2014 · CA
Elucidating the role of NF-kB signaling in rhabdomyocarcoma$295,484
R01 · FY2013 · CA
Elucidating the role of NF-kB signaling in rhabdomyocarcoma$318,292
R01 · FY2012 · CA
Therapeutic Targets in Alveolar Rhabdomyosarcoma$309,354
R01 · FY2012 · CA · contact PI
Elucidating the role of NF-kB signaling in rhabdomyocarcoma$335,221
R01 · FY2011 · CA
Therapeutic Targets in Alveolar Rhabdomyosarcoma$318,695
R01 · FY2011 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$215,999
R01 · FY2010 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$168,187
R01 · FY2010 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$145,134
R01 · FY2010 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$307,532
R01 · FY2009 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$78,647
R01 · FY2009 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$76,396
R01 · FY2009 · CA · contact PI
Therapeutic Targets in Alveolar Rhabdomyosarcoma$307,100
R01 · FY2008 · CA · contact PI
Conditional Mouse Model of Alveolar Rhabdomyosarcoma$68,850
K08 · FY2006 · CA · contact PI
Conditional Mouse Model of Alveolar Rhabdomyosarcoma$137,700
K08 · FY2005 · CA
Conditional Mouse Model of Alveolar Rhabdomyosarcoma$140,130
K08 · FY2004 · CA
Conditional Mouse Model of Alveolar Rhabdomyosarcoma$140,130
K08 · FY2003 · CA
Conditional Mouse Model of Alveolar Rhabdomyosarcoma$70,065
K08 · FY2002 · CA
Conditional Mouse Model of Alveolar Rhabdomyosarcoma$140,130
K08 · FY2001 · CA